Who are Monosialoganglioside GM1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hu3F8, Ch14.18, DANYELZA, GM1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/monosialoganglioside-gm1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Monosialoganglioside GM1 — Competitive Intelligence Brief

Monosialoganglioside GM1 (Monosialoganglioside GM1) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ganglioside. Area: Neurology.

marketed Ganglioside Growth factor receptors; neuronal cell surface ganglioside receptors Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Monosialoganglioside GM1 (Monosialoganglioside GM1) — General Hospital of Shenyang Military Region. Monosialoganglioside GM1 is a ganglioside that promotes neuronal repair and regeneration by enhancing neurite outgrowth and protecting neurons from damage.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Monosialoganglioside GM1 TARGET	Monosialoganglioside GM1	General Hospital of Shenyang Military Region	marketed	Ganglioside	Growth factor receptors; neuronal cell surface ganglioside receptors
Hu3F8	NAXITAMAB	Y-Mabs Therapeutics Inc	marketed	Glycolipid Disialoganglioside-directed Antibody [EPC]		2020-01-01
Ch14.18	DINUTUXIMAB	United Therap	marketed	Glycolipid Disialoganglioside-directed Antibody [EPC]	GD2	2015-01-01
DANYELZA	NAXITAMAB-GQGK	Y-MABS THERAPEUTICS INC	marketed	Glycolipid Disialoganglioside-directed Antibody [EPC]	GD2
GM1	GM1	Qilu Pharmaceutical Co., Ltd.	phase 3	Ganglioside	Growth factor receptors (indirect); neuronal cell surface ganglioside

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ganglioside class)

General Hospital of Shenyang Military Region · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Monosialoganglioside GM1 — Competitive Intelligence Brief. https://druglandscape.com/ci/monosialoganglioside-gm1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab